- Home
- AGX vs MLTX Comparison
AGX vs MLTX Comparison
Compare AGX & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGX
- MLTX
- Stock Information
- Founded
- AGX 1961
- MLTX 2021
- Country
- AGX United States
- MLTX Switzerland
- Employees
- AGX N/A
- MLTX N/A
- Industry
- AGX Engineering & Construction
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- AGX Consumer Discretionary
- MLTX Health Care
- Exchange
- AGX Nasdaq
- MLTX Nasdaq
- Market Cap
- AGX 3.0B
- MLTX 2.8B
- IPO Year
- AGX N/A
- MLTX N/A
- Fundamental
- Price
- AGX $259.72
- MLTX $54.16
- Analyst Decision
- AGX Buy
- MLTX Strong Buy
- Analyst Count
- AGX 3
- MLTX 7
- Target Price
- AGX $210.00
- MLTX $74.83
- AVG Volume (30 Days)
- AGX 415.7K
- MLTX 753.2K
- Earning Date
- AGX 09-04-2025
- MLTX 11-06-2025
- Dividend Yield
- AGX 0.58%
- MLTX N/A
- EPS Growth
- AGX 160.19
- MLTX N/A
- EPS
- AGX 8.31
- MLTX N/A
- Revenue
- AGX $920,885,000.00
- MLTX N/A
- Revenue This Year
- AGX $11.84
- MLTX N/A
- Revenue Next Year
- AGX $20.79
- MLTX N/A
- P/E Ratio
- AGX $31.07
- MLTX N/A
- Revenue Growth
- AGX 29.16
- MLTX N/A
- 52 Week Low
- AGX $87.79
- MLTX $31.42
- 52 Week High
- AGX $262.00
- MLTX $61.87
- Technical
- Relative Strength Index (RSI)
- AGX 64.81
- MLTX 48.63
- Support Level
- AGX $202.25
- MLTX $50.84
- Resistance Level
- AGX $245.00
- MLTX $61.30
- Average True Range (ATR)
- AGX 12.42
- MLTX 3.01
- MACD
- AGX 3.05
- MLTX -0.70
- Stochastic Oscillator
- AGX 96.50
- MLTX 30.10
About AGX Argan Inc.
Argan Inc is a United States-based construction firm that conducts operations through its wholly-owned subsidiaries, GPS, APC, TRC, and SMC. Through GPS and APC it provides a full range of engineering, procurement, construction, commissioning, maintenance, project development and technical consulting services to the power generation market, including the renewable energy sector, for a wide range of customers, including independent power project owners, public utilities, power plant heavy equipment suppliers and other commercial firms with power requirements in the U.S., Ireland and the U.K. It operates in three segments: Power Services, Industrial Services, and Telecom Services, out of which Power Services derives the majority of revenue.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.